By Justin Petrone

While many economists and analysts are projecting a diminished National Institutes of Health budget next year, Illumina's CEO doesn't believe such cuts will have a negative impact on the company's business.

Not only are these estimates gloomier than Illumina's internal projections, but the company is still seeing rising demand for next-gen sequencing as well as increasing array sales to applied markets such as agricultural biotechnology research and forensics, he said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Human Longevity alleges that Craig Venter stole trade secrets in a lawsuit filed against the J. Craig Venter Institute.

A new analysis critiques the analysis and conclusions of the Atacama mummy genome sequencing study.

In PLOS this week: transcription levels linked to uracil mutations, transcriptomic analysis of medicinal leech, and more.

An Associated Press poll finds that most US adults say they'd want to know whether they carried a gene variant predisposing them to an incurable disease.